These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32592183)

  • 1. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
    Devinsky O; Thiele EA; Wright S; Checketts D; Morrison G; Dunayevich E; Knappertz V
    Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
    Bialer M; Perucca E
    Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
    Lattanzi S; Trinka E; Striano P; Zaccara G; Del Giovane C; Nardone R; Silvestrini M; Brigo F
    Epilepsia; 2020 Jun; 61(6):1090-1098. PubMed ID: 32452532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
    Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
    Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
    Patsalos PN; Szaflarski JP; Gidal B; VanLandingham K; Critchley D; Morrison G
    Epilepsia; 2020 Sep; 61(9):1854-1868. PubMed ID: 32918835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Talwar A; Estes E; Aparasu R; Reddy DS
    Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
    Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
    VanLandingham KE; Crockett J; Taylor L; Morrison G
    J Clin Pharmacol; 2020 Oct; 60(10):1304-1313. PubMed ID: 32652616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
    García-Peñas JJ; Gil Nagel-Rein A; Sánchez-Carpintero R; Villanueva-Haba V
    Rev Neurol; 2021 Sep; 73(S01):S1-S8. PubMed ID: 34486101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.
    Anderson LL; Absalom NL; Abelev SV; Low IK; Doohan PT; Martin LJ; Chebib M; McGregor IS; Arnold JC
    Epilepsia; 2019 Nov; 60(11):2224-2234. PubMed ID: 31625159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
    Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
    CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
    Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
    Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis.
    Devi N; Madaan P; Ameen R; Sahu JK; Bansal D
    Seizure; 2022 Jul; 99():164-175. PubMed ID: 35487871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome.
    Tolbert D; Chu HM; Ette EI
    Epilepsy Res; 2019 Nov; 157():106182. PubMed ID: 31563030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
    Savage TE; Sourbron J; Bruno PL; Skirvin LA; Wolper ES; Anagnos CJ; Thiele EA
    Epilepsy Res; 2020 Feb; 160():106263. PubMed ID: 31923763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
    Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
    Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome.
    Besag FMC; Vasey MJ
    Expert Opin Pharmacother; 2019 Sep; 20(13):1563-1574. PubMed ID: 31373526
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
    Franco V; Perucca E
    Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis for the Treatment of Epilepsy: an Update.
    Gaston TE; Szaflarski JP
    Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.